Our Pipeline MLR 1023 (type II diabetes)

Click chart for a larger view.

The company's most advanced program is focused on the development of MLR-1023, a previously evaluated, clinical-stage drug candidate. Melior has identified a potential new therapeutic use for MLR-1023 in the treatment of Type II diabetes. MLR-1023 compares favorably to both approved drugs and development stage candidates for diabetes. Thus, in animal models, MLR-1023 demonstrates equivalent efficacy to metformin (Glucophage) at a lower dose. In addition, the pre-clinical side-effect profile of MLR-1023 compares favorably to approved drugs. MLR-1023 is orally bioavailable (unlike GLP-1 inhibitors and insulin, which must be administered by injection), does not produce weight gain (in contrast to the glitazones/thiazolidenediones and sulphonylurea classes of drugs) and does not produce hypoglycemia (which metformin is prone to do if not administered with food).

Melior expects to file an Investigational New Drug (IND) application for MLR-1023 during the first quarter of 2007.

More than 150 million people worldwide have diabetes, with approximately 90% suffering from Type II diabetes. An estimated 16 million people in the United States suffer from Type II diabetes, which is often part of a metabolic syndrome that includes obesity, elevated blood pressure and high levels of blood lipids. About 80% of people with Type II diabetes mellitus are overweight.

Back to top of page